Benitec Biopharma Inc. · NASDAQ:BNTC
Benitec Biopharma — Cowen US Investor Showcase (January 2013)
13 slides from Benitec Biopharma's conference presentation, January 2013
Slide 1: Benitec Biopharma's ddRNAi Technology: The next therapeutic revolution
Benitec'Biopharma’s'' ddRNAi'Technology' The next therapeutic revolution January 2013
Slide 2: Forward looking statements
This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Benitec Biopharma can give no assurance that these expectations will prove to be correct. Act
Slide 3: Aim and Strategy
To create appropriate return on AIM investment by commercializing CSIRO gene silencing technology. To demonstrate the applicability of our STRATEGY technology in human disease. To execute commercial partnerships with global pharmaceutical companies
Slide 4: Benitec Biopharma Ltd
Benitec Biopharma Ltd ASX: BLT Selected pipeline programs fulfil critical unmet medical needs. Dominant global IP “Turns off” (silences) disease-causing genes Induces patients’ cells to continuously manufacture the silencing RNA A single administration.
Slide 5: Pathways to Revenue
Pathways to Revenue Advance in-house pipeline programs to the clinic then seek to partner Out-license other targets for ddRNAi technology to biotech and pharma companies
Slide 6: Pipeline and Licensed Programs
Pipeline and Licensed Programs Indication Partners/Collaborators Discovery Pre-clinical Clinical HIV/AIDS Calimmune Out-licensed Acquired from Hepatitis C Tacere/Pfizer Non Small Cell Lung Cancer * University of New South Wales Cancer associated pain Stanford University Hepatitis B Biomics Biotechno
Slide 7: Hepatitis C is a "hot" therapeutic area
Hepatitis C is a “hot” therapeutic area Nov 2011 Gilead paid $11 billion to buy Pharmasset Jan 2012 BMS paid $2.5 billion to buy Inhibitex (INX-189 drug) Achillion projected HCV treatments to generate $20 billion revenue by end of decade Merck goal …"We would consider small deals to large deals, wha
Slide 8: Hepatitis C is a "hot" therapeutic area
Hepatitis C is a “hot” therapeutic area Gilead announced compound failure to Mar 2012 suppress HCV in some patients Aug 2012 BMS announced withdrawal of Inhibitex drug due to safety issues FDA placed Novartis-Idenix drug on clinical hold due to safety concerns
Slide 9: Key Next Steps for HCV Program
Key Next Steps for HCV Program Meeting with the Final pre-IND meeting NIH Recombinant with FDA Advisory Committee Filing of the IND Dosing of first patient
Slide 10: Experienced Leadership Team
Experienced Leadership Team Dr Michael Graham Iain Ross John Chiplin Peter Francis CSO NED NED Chairman Greg West Carl Stubbings Mel Bridges Chief Business Peter French CFO Officer NED CEO
Slide 11: Financial Information
Share price at 30 September 2012 AUD $0.016 per share Financial Information Market capitalisation AUD$ 15.5 million Issued equity: ordinary shares 970,628,529 Options on issue 428,985,202 Share price movements Cash balance at 30 June 2012 AUD$ 3.1 million Operational monthly burn rate for the AUD$ 2
Slide 12: Summary
Summary Potent long-lasting gene Multiple patent protection silencing platform world wide technology from CSIRO Proven pre-clinical and Broad pipeline in clinical efficacy and multiple very high value safety therapeutic areas
Slide 13: Carl Stubbings, Chief Business Officer
Carl Stubbings Chief Business Officer Benitec Biopharma Ltd. +61 (0)423 666 374 [email protected] www.benitec.com
Benitec Biopharma — Cowen US Investor Showcase (January 2013) on 6ix